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Abstract 
The estimand framework included in the addendum to the ICH E9 guideline facilitates discussions 
to ensure alignment between the key question of interest, the analysis, and interpretation. 
Therapeutic knowledge and drug mechanism play a crucial role in determining the strategy and 
defining the estimand for clinical trial designs. Clinical trials in patients with hematological 
malignancies often present unique challenges for trial design due to complexity of treatment 
options and existence of potential curative but highly risky procedures, e.g. stem cell transplant or 
treatment sequence across different phases (induction, consolidation, maintenance). Here, we 
illustrate how to apply the estimand framework in hematological clinical trials and how the 
estimand framework can address potential difficulties in trial result interpretation. 
 
This paper is a result of a cross-industry collaboration to connect the International Conference on 
Harmonisation (ICH) E9 addendum concepts to applications. Three randomized phase 3 trials will 
be used to consider common challenges including intercurrent events in hematologic oncology 
trials to illustrate different scientific questions and the consequences of the estimand choice for 
trial design, data collection, analysis, and interpretation. Template language for describing 
estimand in both study protocols and statistical analysis plans is suggested for statisticians’ 
reference. 
 
Key Words: Estimand, hematology clinical trials, Intercurrent events, ICH E9 addendum 
 
 
Section 1: Introduction  
 
The key questions of interest in a clinical trial vary from one stakeholder to another. The current 
practice of defining trial objectives rather vaguely has led to various challenges in interactions 
with different stakeholders, including regulators and payers. To improve transparency and ensure 
alignment between trials objectives,  data collection and statistical approaches, it appears 
necessary to go back to the first principles and to clearly define what is to be estimated.   
The addendum to the ICH E9 guideline was released in 2019 to introduce the estimand 
framework. This framework targets to align the clinical trial objectives with the design and 
statistical analyses by providing detailed definitions of the quantity of scientific interest 
 (“estimand”). Besides estimands, the addendum also discusses the role of sensitivity and 
supplementary analyses. Therapeutic knowledge and drug mechanism play a crucial role in 
determining the estimand of interest and the design (Kenneth 2020).  
In recent years, many clinical trials have been initiated in hematologic malignancies due to an 
enhanced understanding of cancer pathologies (Palmisiano 2018). Hematological malignancies 
such as leukemia, multiple myeloma and lymphoma represent a subset of indications in 
hematologic oncology (referred to as “hematology” for simplicity below).  Clinical trials in 
hematologic malignancies are characterized by specific definition of endpoints, data collection, 
magnitude of clinically meaningful treatment effect, and interpretation of treatment effect.  
Moreover, standard therapies are often following a sequence of treatment (e.g. induction, 
consolidation, maintenance) and offering stem cell transplantation can be an important part of 
such a treatment strategy. This can lead to challenges when defining the treatment attribute of an 
estimand (Roussel 2019, Salwender 2019). Time-to-event (TTE) endpoints are mainstays of late 
phase hematology clinical trials. Though, overall survival (OS) is considered the gold standard 
for determining treatment efficacy in oncology trials, but OS can be challenging to assess 
because of long trial durations and the potentially confounding impact of subsequent therapies.  
Therefore, other clinical endpoints like progression-free survival (PFS), event-free survival 
(EFS), time to progression and response rate (RR) may be appropriate endpoints for the 
regulatory approval of treatments (Ellis 2014, Johnson 2003 and Smith 2017).  Some statistical 
analyses may be more intuitive and easier to interpret than others, depending on the key question 
of interest, trial type, patient population, and duration of follow-up. Another typical feature for a 
hematological malignancy is that the broad population defined in a clinical trial for the same type 
of cancer is often heterogeneous in the sense that patients could have very different types of 
genomic characteristics. For example, some patients with diffuse large B cell lymphoma 
(DLBCL) may be curable while others may die quickly irrespective of any treatment options 
available so far (Zhang 2013).   
In this paper, we present the utility of the estimand framework for typical hematology trials and 
provide practical recommendations. The estimand framework lends itself to a more transparent 
way of specifying each objective of a trial and ensuring alignment with the selected 
estimator/analysis method so that the most appropriate methods for primary and sensitivity 
analyses are identified and applied. In this paper we discuss ways to incorporate the estimand 
framework, especially strategies to common intercurrent events when designing a clinical trial 
for hematology malignancies.  Issues relevant to defining estimands are discussed. On the side of 
the estimator,  considerations are given regarding the trial design to minimize dropouts and 
missing values.  In addition, we present real examples to illustrate the application of different 
estimand strategies. 
The rest of the paper is structured as follows. In Section 2, we introduce three typical case trials 
to illustrate the key aspects of the estimand framework for hematology trials.  Section 3 and 4 
focus on the strategies for different intercurrent events and relevant sensitivity analyses and 
supplementary analyses. Finally, the impact of the estimand framework on trial design, data 
collection and data analysis are discussed in Section 5. Section 6 concludes with a discussion. 
Sample language for protocol and statistical analysis plan (SAP) are provided in the Appendix.  
  
Section 2: Motivating examples     
 
We provide three case studies to demonstrate the utility of the estimand framework in 
confirmatory hematology trials. These examples consist of randomized Phase 3 trials with time 
to event endpoint comparing a novel treatment with standard of care (SOC). They include the 
disease areas non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia. The 
purpose of this exercise is to demonstrate the application of the estimand framework in 
hematology to practitioners. We have no intention to comment or judge the clinical activity of 
the drugs involved or related regulatory decisions. Further details of the treatment, population, 
primary endpoint, and design are shown in Table 2 and will be used in later sections for 
introducing appropriate estimands. 
Table 1   Design Specification of Three Examples 
Examples Gallium Study [
 Marcus 2017] 
Multiple Myeloma 
Study a 
RATIFY Study 
[Stone 2017] 
Treatment  
 
Open label 
randomized study 
comparing  
 Obinutuzumab 
 Rituximab  
in combination with 
three backbone 
chemotherapies  
 
Open label 
randomized study 
comparing  
 Drug  X + 
background 
therapy 
 background 
therapy 
Double-blinded study  
 
 Midostaurin 
 Placebo 
in combination with 
chemotherapy  
 
Population Patients with 
untreated advanced 
indolent non-
Hodgkin's lymphoma 
Patients newly 
diagnosed with 
multiple myeloma 
and eligible for high-
dose therapy 
 
Patients with first-
line acute myeloid 
leukemia (AML) 
with a FLT-3 
mutation 
Design 
 
 Induction Phase 
 
 
 
 
 
 
 
 
  
 
 
See Figure 1a 
 
Patients have 
received 
Obinutuzumab or 
Rituximab + 
chemotherapy 
 
 
 
 
 
 
 
See Figure 1b 
 
Patients have 
received drug X + 
background therapy 
or background 
therapy only. 
Induction phase is 
followed by a 
consolidation phase. 
Induction and 
consolidation phase 
will consist of six 28-
day cycles, 4 cycles 
See Figure 1c 
 
Patients have 
received  
midostaurin or 
placebo along with 
chemotherapy for one 
cycle. If there are 
definitive evidence of 
clinically significant 
residual leukemia, a 
second cycle of same 
therapy continues. 
Induction phase is 
  
 
 
Maintenance Phase 
 
 
 
 
 
Participants achieving 
response (Complete 
response [CR] or 
partial response [PR]) 
continue the 
treatment with the 
antibody only until 
disease progression. 
Those with stable 
disease (SD) undergo 
the same schedule of 
assessments, but do 
not receive further 
therapy.  
 
of induction, 
followed by ASCT, 
then 2 cycles of 
consolidation 
 
 
Patients are followed 
by background 
maintenance therapy 
with or without drug 
X until disease 
progression or 
unacceptable toxicity 
followed by 4 cycles 
of consolidation 
 
 
Patients who 
remained in 
remission entered a 
maintenance phase in 
which they received 
drug A or placebo. 
Primary Endpoint Progression-free 
survival  
 
Progression-free 
survival  
 
Overall survival 
Sample Size (events) 1202  690 717 
    
a: This study is still ongoing  
Further details of the three trial designs are schematically shown in Figure 1. For all three 
studies, the design has two phases: induction and maintenance. In addition to that the multiple 
myeloma and the RATIFY trial also have a consolidation phase. During the induction (or 
consolidation) phase, patients are treated aggressively with the experimental drug and/or SOC.  
This is followed by maintenance therapy until disease progression or unacceptable toxicity. For 
all the trials, the comparisons are made with a primary endpoint which is measured over all 
phases following a traditional intent to treat (ITT) principle. However, the design cannot address 
other important  clinical questions such as the benefit of treatment in each phase due to the 
occurrence of different intercurrent events (e.g., start of maintenance therapy, stem cell 
transplantation (ASCT or HSCT), possible response or remission which decides the maintenance 
therapy etc.).  Key assumption like proportional hazard between two treatment groups is 
questionable in presence of these intercurrent events (e.g., ASCT may change the disease course 
completely). Other challenges include interest in additional patient populations (marginal-zone 
lymphoma (MZL) in Gallium trial, for which the primary interest is in follicular lymphoma (FL) 
patients), discrepancies between investigator and independent reviewer regarding the assessment 
of progression, and assessment of secondary endpoints (e.g., event-free survival, EFS). In the 
next section we show how the five estimand attributes can be used to address these issues and 
answer appropriate clinical questions of interest. 
 
  
 
Figure 1: Schematic Overview of the Study Designs for Three Examples  
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1b:  Multiple Myeloma Study 
Patients newly 
diagnosed with 
multiple 
myeloma and 
eligible for high-
dose therapy 
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For all the examples above, intent-to-treat (ITT) analyses were planned for the primary analysis. 
The clinical meaningfulness of such estimates needs to be assessed as this does not consider that 
some patients take new anti-cancer therapy during the trial. This may convolute the overall 
biological effect of the treatment. For example, consider a situation where most patients on 
placebo switch to a new anti-cancer therapy but only a few on the active drug switch. In this 
case, the ITT analysis essentially compares the new drug with another anti-cancer therapy, rather 
than with placebo. Moreover, a series of sensitivity analysis are often pre-specified in the 
analysis plan to show robustness of the treatment effect. Often, these analyses lack the 
description of the underlying estimand which creates issues with clinical interpretation. In the 
next section we show the utility of the estimand framework to address these challenges. 
 
Section 3: Application of the estimand framework in hematologic oncology  
 
In this section we discuss how the key questions in hematological studies can be viewed in the 
estimand framework. Based on the ICH E9 addendum it is defined through the five attributes viz, 
treatment, population, variable, intercurrent event, and population-level summary. Each 
intercurrent event and associated strategy needs to be clearly stated. Intercurrent events are 
clinical events that occur after treatment initiation that affect either the interpretation or the 
existence of the measurements associated with the clinical question of interest . Some potential 
examples of intercurrent events in hematology trials are discontinuation of treatment, start of 
maintenance therapy, or treatment switching. The treatment effect is quantified using a 
population-level summary. There could be multiple ways of describing the same estimand. For 
example, a composite strategy for an intercurrent event of subsequent therapy  together with the 
endpoint of PFS is the same as treatment policy strategy for an intercurrent event of subsequent 
therapy when the endpoint is defined as EFS, which is time interval from randomization to the 
earliest of PD, subsequently therapy or death.  
1c:  RATIFY Study 
 All these case studies in Section 2 are large phase 3, randomized, controlled trials in patient 
populations with different hematologic indications and represent typical trial designs in 
hematology drug development. For each example, we now describe the primary scientific 
question and the corresponding five estimand attributes. These examples help practitioners to 
understand how to explain the key question of interest using the estimand framework in the study 
protocol and analysis plan.  All the details are provided in Table 2.  Note that these trials were 
designed and executed prior to the release of the ICH E9 addendum. Therefore, this exercise is 
performed retrospectively for illustration purposes only. 
The case studies represent typical treatment approaches in hematologic indications consisting of 
different treatment parts. The experimental treatment is often added to the standard of care 
treatment. Trial designs comparing treatment strategies (combination or treatment sequence) will 
allow proper assessment of the whole strategy. However, it is extremely difficult if not 
impossible to estimate the contribution of an individual component of the strategy unless 2nd 
randomization or multiple trials are implemented. Health authorities might request such 
information if  some parts of the treatment strategy are not well established like the maintenance 
treatment in AML or myeloma. With the estmand framework, there is no ambiguity about what 
treatment effect the study is designed to establish. 
The same considerations apply to stem cell transplantation (SCT). In many hematologic diseases, 
SCT is part of the standard treatment options. In AML, SCT improves the chance of cure but 
relates also to specific risks like graft-vs-host disease or transplant-related mortality. As such, 
SCT might impact the results for OS or PFS.  The question is whether we need to assess the 
impact of SCT on OS or PFS. However, the receiving SCT might be a result of the experimental 
therapy and thus, assessing the contribution of the elements of a treatment strategy might be 
challenging or even not be feasible. Assessing the effect of the whole treatment strategy 
integrating all its components might be the most relevant approach for the patients. The estimand 
framework will facilitate these discussions with the health authorities prior to starting a study. 
More specifically, sponsor and the health authority can agree on what can be estimated and what 
cannot be estimated at design stage. 
 
 
 Table 2: Attributes of  Estimands as per ICH E9 Addendum for Three Case Studies 
 
Gallium study Multiple myeloma 
study 
RATIFY study 
Scientific 
question 
Will the addition of 
Obinutuzumab to FL 
patients treatment 
strategy prolong the 
time to death and 
progression regardless 
of new anti-lymphoma 
treatments prior to 
experiencing a PFS 
event 
Will the addition of new 
drug to VRd to a 
treatment strategy 
consisting of induction, 
ASCT, consolidation 
and maintenance 
prolong the time to 
death and progression 
compared to VRd alone 
if patients with new 
therapy  would have had 
the same subsequent 
event hazards as patients 
without new therapy, 
had they not taken new 
therapy 
Will the addition of 
Midostaurin to newly 
diagnosed AML treatment 
strategy prolong the time 
to death regardless of new 
therapies and SCT 
Primary 
Objective 
To evaluate the efficacy 
of G‑chemo followed 
by G‑maintenance 
therapy compared with 
R‑chemo followed by 
R‑maintenance therapy 
in patients with 
previously untreated 
advanced FL, as 
measured by 
investigator‑assessed 
PFS. 
To evaluate the efficacy 
of the new drug to a 
standard care VRd as a 
treatment sequence in 
patients with newly 
diagnosed multiple 
myeloma who are 
transplant eligible in 
terms of PFS using 
algorithm. 
To evaluate benefit of 
Midostaurin in addition to 
the standard care in 
prolonging overall 
survival compared with 
the standard care in 
patients newly diagnosed 
AML treatment strategy 
irrespective of any 
supportive care and 
subsequent therapy use. 
Treatment  Patients receive 6 or 8 
induction cycles of 
induction 
chemoimmunotherapy. 
Responding patients 
receive single agent 
therapy during 
maintenance therapy for 
up to 2 years  
Patients receive 4 cycles 
induction therapy. 
Responding patients 
receive ASCT followed 
by 2 cycles of 
consolidation therapy. 
Thereafter patients are 
entering maintenance 
therapy  
Patients receive 1 cycle 
induction therapy. If no 
remission, 2nd induction 
cycle is given. Eligible 
patients receive SCT. 
Otherwise up to 4 cycles 
of consolidation. After 
consolidation patients 
receive 12 cycles single-
agent maintenance 
treatment  
 Population FL patients as defined 
by protocol eligibility 
criteria 
MM patients as defined 
by protocol eligibility 
criteria 
First-line AML patients 
as defined by eligibility 
criteria 
Variable PFS defined as time 
from randomization to 
PD as per investigator 
assessment or death, 
whichever is earlier 
PFS by algorithm based 
on lab data and clinical 
data 
OS 
Intercurrent 
events and 
strategies  
 
1: New anti-
cancer therapy 
prior to PFS 
event 
Treatment Policy: 
intercurrent event is 
ignored#, PFS time 
irrespective of start of 
new therapies is 
considered 
Hypothetical:  Patients 
who received anti-
cancer therapy are 
assumed to have the 
same risk as those who 
did not receive 
subsequent anti-cancer 
therapy  
Treatment Policy: 
intercurrent event is 
ignored, entire survival 
time after starting new 
therapies is taken into 
account 
2: Treatment 
discontinuation 
Treatment Policy: 
intercurrent event is 
ignored#  
Treatment Policy: 
intercurrent event is 
ignored 
Treatment Policy: 
intercurrent event is 
ignored 
Population-
level summary 
 Hazard ratio* Hazard ratio* Hazard ratio* 
#: The occurrence of the intercurrent event is considered irrelevant in defining the treatment 
effect of interest  
*Hazard ratio calculated using stratified cox regression with treatment as the only covariate 
 
The estimands described in Table 2 clearly define what is to be estimated and how to estimate  
treatment benefit based on the scientific questions of interest. The estimand framework ensures 
consistency of the choice of statistical analysis with the scientific question of interest (Holzhauer 
2015). This avoids misalignment between the trial objectives, analysis, and  interpretation of 
result (Akacha 2017). Different strategies used to address intercurrent event of subsequent 
therapy address different clinical questions and this becomes clearer when embedding these 
clinical questions in the estimand framework. Different stakeholders will likely be interested in 
different scientific questions. For example, health authorities may be interested in the OS benefit 
irrespective of subsequent anti-cancer therapy while HTA (Health Technology Assessment) is 
interested in the OS benefit if no subsequent anticancer is allowed. 
Under the estimand framework, ambiguity of interpretation of trial results will be eliminated or 
minimized. Each scientific question of importance can be addressed by the mutual agreement of 
 estimand description between trial sponsor and the targeted stakeholder (health authorities, HTA, 
patients, etc.) for assessing the trial results. 
 
Section 4: Sensitivity analysis vs Supplementary analysis - 
 
Description of estimand as illustrated in case studies in Section 3 above includes the main 
estimator or summary of treatment effect. The ICH E9 addendum also provides guideline to 
assess the robustness of treatment effect. An estimand is associated with one specific scientific 
question of interest. However, there could be multiple scientific questions that need to be 
answered from a clinical trial to establish the benefit of a treatment intervention. Consequently, 
there are two types of analyses that are important in understanding the impact of treatment 
intervention.  
Sensitivity analyses are a series of analyses targeting the same estimand. This means there is 
usually no change to the treatment, population, variable,  handling of intercurrent events, and 
population-level summary measure. These analyses assess different assumptions of the statistical 
methods to explore the robustness of the statistical inference, such as the main estimator and 
deviations from its underlying modelling assumptions or limitations in the data (Mehrotra 2016). 
Note that this redefines the term “sensitivity analyses” compared to its traditional pre-addendum 
use. 
Supplementary analyses target a different estimands of interest. This section focuses on 
sensitivity and supplementary analysis for PFS and OS, illustrated by the case studies introduced 
in Section 2. Please note the recommendation below is linked to the GALLIUM study only. In 
general, whether analyses are sensitivity or supplemental, or appropriate at all, is dependent on 
the particular context and strategy. Different analyses may serve as the primary analyses for 
different stakeholders. A supplementary analysis for one stakeholder or in particular context may 
be the primary or a sensitivity analysis for another stakeholder or in another context. 
 
 
Section 4.1 Progression Free Survival 
 
In this section, we provide the working group’s recommendations how to embed these analyses 
for PFS in the addendum’s framework of primary, sensitivity, and supplementary analyses. 
Progression free survival is defined as the time from randomization until death from any cause or 
objective disease progression. PFS is an acceptable endpoint for oncology treatment approval in 
many tumor types (FDA guidance 2018) . Table 3 summarizes common analyses performed for 
PFS using Gallium study for illustration purpose in addition to the main analysis as stated in 
Section 3. The primary analysis is a stratified Cox regression analysis based on investigators’ 
assessed PFS irrespective of any subsequent anti-cancer therapy use. The main analysis is 
aligned with the scientific question presented in Table 2.The concept described in here applies 
also to related endpoint definitions like event-free survival (EFS) in AML. 
  
 
Table 3: Common analyses performed for endpoint PFS (GALLIUM study) 
 
Analysis 
method 
Key 
assumptions 
Sensitivity or 
supplementary 
Rationale Recommendation 
Same analysis 
as main analysis 
except for using 
PFS by 
independent 
review 
committee 
(IRC-PFS) 
IRC-PFS is 
perceived as less 
biased compared 
with INV-PFS 
since this is an 
open-label 
study. As in the 
main analysis, 
patients are 
assumed to be 
consistently 
followed beyond 
subsequent 
therapy 
Sensitivity 
analysis 
Analysis 
corresponds to the 
same primary 
estimand as stated 
in the Table 2. It is 
considered as data 
limitation for 
disease assessment 
Same disease 
assessment 
criteria should be 
used for both 
investigators’ 
assessment and 
IRC assessment. 
IRC assessment 
may introduce 
bias due to 
informative 
censoring 
Unstratified Cox 
regression  
Common 
baseline risk 
among different 
strata 
Sensitivity 
analysis 
Same estimand as 
in Table 2. The 
main analysis 
assumes different 
baseline risk across 
different strata. 
This analysis is 
based on an 
assumption  which 
deviates  from the 
assumption used in 
the main analysis 
Useful analysis 
for checking 
robustness of the 
main analysis 
Same analysis 
as the main 
analysis except 
for imputing the 
event time of 
subjects 
considered to 
have 
problematic 
informative 
censoring 
[Liu 2017] 
Informative 
censoring 
Sensitivity 
analysis 
To demonstrate the 
impact of 
violations in 
necessary 
assumptions, and 
assesses robustness 
of the p-value as 
calculated from 
imputed data as 
compared with un-
imputed data 
Checking if the 
distribution of 
censoring was 
approximately 
random or 
balanced 
between the arms 
Censoring for 2 
or more 
consecutive 
Non-informative 
missing  
Sensitivity 
analysis 
Targets the same 
estimand. It is 
considered as data 
limitation and 
In some cases, if 
the consecutive 
missing is due to 
an intercurrent 
 missing 
assessment(s) 
missing assessment 
is assumed to be 
non-informative  
event such as 
health care 
facility closure 
temporally due to 
pandemic, then  
it can be viewed 
as supplementary 
analysis since it 
corresponds to a 
different 
estimand 
(hypothetical, see 
Degtyarev 2020)  
Analysis using 
per-protocol 
(PP) population 
PP population 
represents a 
subset of 
patients, which 
adhere to  the 
protocol defined 
condition.  
Supplementary 
analysis 
Addresses the 
population attribute 
of estimand. PP  
population 
definition often 
depends on the 
outcome of 
treatment, such as 
completing a 
minimum of 6 
cycles of treatment.  
It is highly 
recommended 
not to have any 
such analysis. 
Patients in PP 
population do 
not represent 
random samples 
of the target 
population as 
defined by the 
eligibility 
criteria. 
Consequently, 
the interpretation 
is very difficult 
and such analysis 
is not useful.  
Censoring at 
subsequent 
therapy 
Subsequent 
therapy impacts 
the 
interpretation of 
treatment effect 
Supplementary 
analysis 
Different strategy 
for intercurrent and 
hence it 
corresponds to 
different estimand. 
It is a hypothetical 
strategy and 
estimation via 
simple censoring 
assumes non-
informative 
censoring at 
subsequent therapy 
use 
Useful analyses 
to understand the 
treatment effect 
from different 
perspectives. In 
the past, the 
FDA could 
accept this as the 
main analysis 
while the EMA 
often preferred 
treatment policy 
strategy for the 
intercurrent 
event of 
subsequent 
therapy 
 covariate-
adjusted 
analysis (multi-
variate Cox 
regression 
analysis) 
[Permutt 2020] 
Covariates may 
be confounding 
factors for 
disease outcome 
and imbalance 
may exist 
between two 
treatment arms 
Supplementary 
analysis 
The analysis 
addresses a 
different scientific 
question. i.e., what 
is the treatment 
benefit of 
Obinutuzumab in 
terms of PFS for 
patients who have 
covariates valued 
at population 
means.  Covariate 
adjusted 
multivariate Cox 
regression provides 
a conditional 
treatment effect 
rather than 
marginal treatment 
effect.  
Interpretation 
should be 
careful, and 
results may not 
be consistent 
since it does not 
address the same 
estimand 
 
 
Section 4.2 Overall Survival 
 
Now, we provide some recommendations how to embed  addendum’s framework of primary, 
sensitivity, and supplementary analyses for Overall Survival (OS). Overall survival is defined as 
the time from randomization until death from any cause. Survival is considered the most reliable 
cancer endpoint, and when trials can be conducted to adequately assess survival, it is the 
preferred endpoint ( FDA Guidance 2018, EMA/CHMP Guidance 2017). OS is often performed 
based on survival data collected in the study for all patients. Table 4 lists common analyses 
performed for OS in addition to the main analysis as stated in Section 3, which is the stratified 
Cox regression analysis using the survival data collected in the entire study duration ignoring any 
subsequent anti-cancer therapy use. 
 
Table 4: Common analyses performed for endpoint OS  
 
Analysis 
method 
Key 
assumptions 
Sensitivity or 
supplementary 
Rationale Recommendation 
Censor at 
subsequent anti-
cancer therapy 
 
Patients who 
received 
subsequent anti-
cancer therapy 
have the same 
risk as those 
who did not 
receive 
Supplementary 
analysis 
Using the 
hypothetical 
strategy to account 
for the intercurrent 
event, new 
anticancer therapy, 
which is a new 
estimand. 
Not very useful 
since it is 
unlikely that 
assumption holds 
 subsequent anti-
cancer therapy  
Rank preserving 
structural failure 
time (RPSFT) 
model 
Treatment effect 
is the same 
regardless of 
when the 
experimental 
treatment is 
initiated  
Supplementary 
analysis 
The analysis is to 
address a different 
question: what is 
the treatment 
benefit if patients 
in the Rituximab 
arm are not 
allowed to receive 
Obinutuzumab 
after PD. The 
treatment effect is 
expressed as an 
acceleration factor 
through G-
estimation or by 
estimating hazard 
ratios using 
reconstructed data 
through the Cox 
model. Different 
strategy (an 
alternative 
hypothetical 
strategy) for 
intercurrent of 
treatment crossover 
(control to 
experiment arm). 
Hence it 
corresponds to 
different estimand. 
Useful analysis 
to adjust for 
crossover. This 
method is 
advantageous as 
it preserves 
randomization, 
does not require 
information on 
covariates and 
can handle larger 
proportion of 
patient 
switching. 
This analysis is 
often of interest 
to the HTA for 
reimbursement 
decision 
Inverse 
Probability 
Censoring 
Weighting 
(IPCW) analysis 
All common 
predictors for 
survival and/or 
the probability 
of treatment 
switching are 
measured  
 
Supplementary 
analysis 
The corresponding 
scientific question 
is “what would be 
the treatment 
difference if 
subsequent anti-
cancer therapies are 
not available?” It is 
one of hypothetical 
strategies used for 
intercurrent event 
of subsequent anti-
cancer therapy.  
Clinical 
interpretation is 
very different 
from the main 
OS analysis. 
However, it 
provides some 
insight in 
understanding 
the impact of 
treatment 
intervention. 
This analysis is 
often of interest 
to the HTA for 
 reimbursement 
decision 
Two-stage 
approach 
(Latimer 2014, 
Alshurafa 2012) 
OS benefit 
adjusted for 
treatment 
crossover 
at a specific 
disease-related 
time-point 
progression 
(PD). It requires 
not only the 
complete data 
collection at PD, 
but also the 
assumption that 
switching 
occurs soon 
after PD 
Supplementary 
analysis 
The treatment 
effect for those 
patients who cross 
over is removed, 
i.e. survival time 
after 
progression is 
adjusted using a 
hypothetical 
strategy. The 
treatment effects 
are estimated 
separately for 
crossover patients 
from control group 
and for patients 
originally 
randomized to the 
investigational 
drug group using 
an accelerated 
failure time (AFT) 
model 
The two-stage 
approach  
assumes no 
unmeasured 
confounders. 
This assumption 
can be evaluated 
by running a full 
and reduced 
model for 
comparison. 
 
 
Section 5: Impact on trial design, data collection, and data analysis  
 
The design of a clinical trial needs to be aligned with the choice of estimand or estimands which 
reflects the primary objectives of the clinical trial. The agreed estimands dictate the data that 
needs to be collected. Different estimands might have different requirement of data collection. 
More importantly, a clinical trial may have multiple estimands, which implies that the data 
collection should be determined by the need to address them all (Scharfstein 2019, Section A.4 
of ICH E9 (R1) 2019). 
 
For Gallium study, the study objective was to evaluate the efficacy of G‑chemo followed by 
G‑maintenance therapy compared with R‑chemo followed by R‑maintenance therapy in patients 
with previously untreated advanced FL, as measured by investigator‑assessed PFS. The primary 
estimand was the hazard ratio of G‑chemo followed by G‑maintenance therapy over R‑chemo 
followed by R‑maintenance therapy in the target population, regardless of the subsequent anti-
lymphoma therapy use or whether patients discontinued planed treatment. The study design was 
aligned with the primary objective. If there is another objective to investigate if G-maintenance 
is more efficacious than R-maintenance, then at the end of induction phase, for those who had 
PR or better, they should be re-randomized into G-maintenance or R-maintenance. Similarly, for 
the 2nd and 3rd case study in patients with multiple myeloma and AML respectively, the study 
objective was to evaluate the efficacy of entire treatment sequence (induction followed by 
 consolidation and then maintenance), the design described in Section 2 was the most efficient 
one. However, the design will not allow the causal inference of added effect of the new treatment 
in the maintenance. A potential challenge with this design is that the observed PFS benefit may 
be driven by the benefit of new drug in induction/consolidation only. A 2nd  randomization after 
induction/consolidation would be needed if it is of interest to characterize the maintenance effect. 
 
In both Gallium and RATIFY studies, the strategy for intercurrent events such as subsequent 
therapy and treatment discontinuation is as treatment policy. For the multiple myeloma case 
study, even though the primary estimand used hypothetical strategy for the intercurrent event of 
subsequent therapy, a supplementary analysis corresponding to treatment policy strategy for 
subsequent therapy was planned. Therefore, data for disease assessment should be collected until 
patients progress, or die if no progression or study end, whichever is earlier. The focus of 
discussion has been on the estimand with PFS/OS endpoints so far. In fact, PFS2, which is 
defined from randomization to progression corresponding to the first subsequent therapy or 
death, is also of interest from regulatory perspective in most of cases. Consequently, disease 
assessment, especially PD assessment on the next line subsequent therapy should also be 
collected.  
 
From data analysis perspective, an analytic approach, or estimator, should be aligned with the 
given estimand and should be able to provide an estimate on which a reliable interpretation can 
be based. This implies that any assumptions should be explicitly stated, and sensitivity analyses 
should be carefully described to assess the robustness of the results to the underlying 
assumptions. In Gallium study, analyses performed on PFS included different population (FL 
only and overall population), different censoring schemes, and with or with adjustment for 
stratification and/or baseline covariate (Rufibach 2019). Some of them were targeted on the same 
estimand and should be clarified as sensitivity analysis but others should be specified as 
supplementary analysis to avoid difficulty in interpretation. The subtlety between supplementary 
and sensitivity analysis is illustrated in Section 4. For the 2nd case study in patients with multiple 
myeloma, we may not be able to characterize the benefit magnitude of the new drug when added 
into the lenalidomide for the maintenance for the given study design, however, it is still of 
interest to demonstrate adding the new drug to lenalidomide during the maintenance does 
contribute to the overall benefit as the entire treatment sequence. Therefore, supplementary 
analyses such as treating maintenance as the time dependent covariate or new PFS with reference 
time as the start of maintenance might be to be included in the analysis plan. The treatment 
regimen in the 3rd case study in patients with AML is even more complicated. Like the other 2 
trials, it has multiple treatment phases. In addition, transplantation was performed at the 
discretion of the investigator. The contribution of transplantation to the treatment strategy may 
be of interest. Supplementary analysis to tease out the effect of transplantation should be 
included in the analysis plan even if transplantation itself is part of the treatment regimen. 
 
Section 6: Conclusion and Discussion 
The estimand framework is an efficient tool to ensure consistency between the scientific question 
and the definition of the study objectives. Per E9(R1), intercurrent events are not to be thought of 
as a drawback to be avoided.  Discontinuation of treatment, changing treatment, etc. are part of 
clinical practice and are part of clinical trials.  The framework ensures transparency in 
unfavorable yet unavoidable situations in clinical trials ("intercurrent events"). The outcome of 
studies that are following the estimand framework can be interpreted in a consistent manner 
 (Bengoudifa 2018). We highly recommend estimand(s) to be included in the study protocol and 
details including sensitivity analyses and supplementary analyses to be included in the statistical 
analysis plan (SAP) for the study. Some sensitivity analysis approaches such as tipping point 
analysis recommended in the estimand guidance document but not elaborated in this paper may 
also be considered in the SAP. Recommended template language can be found in the appendix. 
The 3 case studies discussed in this paper represent typical treatment regimens and study designs 
for drug development in hematologic oncology. They share a common feature of having multiple 
treatment phases and the treatment in the follow-up phase may depend on the treatment effect on 
the previous phase. One potential issue with multiphase treatment is the violation of proportional 
hazard assumption for PFS analysis. Assumption of proportional hazard should be checked 
whenever Cox regression model is used. For non-proportional HR, the traditional Cox regression 
model to characterize the treatment benefit using HR may be difficult to interpret (Byod 2012, 
Gregson 2019). Other analysis methods with different population level summary such as 
restricted mean survival time (RMST) analysis and responder analysis using pre-specified 
milestone PFS/OS proportion may need to be adapted. Common intercurrent events and potential 
strategies are discussed in detail for each case study. But the choice of strategies should depend 
on the disease as well as the mechanism of action of the drug (Leuchs 2015, 2017). We only 
illustrated one estimand corresponding to the primary objective in each case study. However, one 
estimand may not be enough for the study objective. For example, in the 2nd case study, 
characterizing the benefit of the new drug when adding in the standard care regimen in induction 
phase, induction/consolidation phase are important together with the overall benefit for the entire 
treatment sequence with long term follow-up are equally important. Especially from regulatory 
perspective, the observed overall treatment benefit is not driven by one single phase. The 
formulation of the scientific question of interest requires an a priori discussion amongst 
stakeholders to tailor the estimand definition and the treatment strategy attribute accordingly:  To 
assess the contribution of each treatment phase of a sequential treatment strategy might require 
re-randomization of eligible patients when starting a subsequent treatment phase. This might 
operationally be not feasible in many hematologic malignancies with rare patient populations. 
 
Another challenge introduced in the Gallium study is the multiplicity control. It is not 
uncommon to include multiple tumor types of the same pathology in one study (both FL and 
MZL in Gallium study). Analysis on different population corresponds to different estimands. So, 
the significance level for the analysis associated with one estimand must be considered in the 
context of the analysis associated with other estimands. In essence, the estimand framework is 
about an estimation (what to estimate and how to estimate). Hypothesis testing is important for 
decision making but it should be handled beyond the estimand framework even though the same 
analytical approach may be used for both hypothesis testing and estimation of treatment effect. 
 
Recently, CAR-T therapies have shown promising results for multiple hematological cancer 
types. The development of CAR-T therapies  poses unique challenges from statistical analysis 
perspective. E.g., bridging treatment is usually allowed during the manufacturing period and 
conditioning lymphodepletion chemotherapy is required before infusion of CAR-T cells 
 (Degtyarev 2019). For single arm study, should the response rate be provided for all patients who 
received CAR-T infusion or for all patients who had apheresis? Similarly, what is the appropriate 
way for measuring treatment benefit for randomized control trials. There won’t be any ambiguity 
for the treatment effect associated with the defined ‘treatment’ (strategy a: sequence of bridging 
treatment, conditioning therapy and infusion of CAR-T vs strategy b: infusion of CAR-T) under 
estimand framework.  Emphasis of this paper is placed on the recommendation of description of 
estimands and careful selection of sensitivity analyses and supplementary analyses for 
hematological trials. Data collection and analysis should also be aligned in coherent manner to 
avoid disconnect between trial objectives and estimands. The template language on estimands for 
protocols and SAPs in the appendix can serve as detailed instructions/ recommendations. 
  
 APPENDIX  
Sample template protocol and statistical analysis plan language (SAP) are provided below using 
GALLIUM study for illustration purpose. Please note that the language below is related to 
estimand only. Hypothesis testing should be included in a separate section independent of 
estimand description  since estimand framework focus on the estimation of treatment effect only.  
Protocol Language  
Italic text is guidance and should be deleted from the final version.  
X. Objectives and Endpoints 
Note: Estimands are not required for all secondary or exploratory endpoints. Only estimands for 
critical secondary endpoints that pertain to regulatory decision-making should be included. If 
needed, the language for secondary endpoint should mimic the primary estimand 
Objective Primary Estimand 
 Population Variable Summary 
Measure 
Treatment  potential 
intercurrent 
events 
The primary trial 
objective is to 
demonstrate 
superiority of the 
experimental over 
the control 
treatment. 
The primary 
comparison of 
progression-free 
survival (PFS) will 
be made regardless 
of whether patients 
withdraw from 
treatment or receive 
new-anti lymphoma 
therapy prior to 
disease progression 
FL patients, 
defined by 
list of in- 
and 
exclusion 
criteria 
Investigator 
assessed 
PFS, 
defined 
from rando 
to PD or 
death 
Hazard 
ratio  based 
on Cox 
regression 
model 
stratified by 
chemotherap
y and 
FLIPI1 
G added to 
chemotherap
y followed 
by G- 
maintenance 
therapy vs R 
added to 
chemotherap
y followed 
by R 
maintenance 
therapy. SCT 
as option.  
(1) New 
anti-
lymphoma 
therapy 
(NALT) 
 
(2) 
treatment 
discontinua
tion  
 
Statistical Analysis Plan Language  
Italic text is guidance and should be deleted from the final version. 
 
 X. Main analytical approach for the primary estimand 
The primary estimand corresponding to the primary endpoint is defined as: 
1. Treatment: 6 or 8 21-day cycles obinutuzumab D1 + C1D8, C1D15: 1000mg/m2 flat + 
site-specific choice of CT (CVP, Benda, CHOP) in induction followed in responding 
patients by 1000mg flat every 2 months until PD or up to 2y with 6 or 8 21-day cycles 
rituximab 375mg/m2 D1 + site-specific choice of CT (CVP, Benda, CHOP) in induction 
followed in responding patients by 375mg/m2 every 2 months until PD or up to 2y 
2. Population: first-line follicular lymphoma patients as defined by the inclusion and 
exclusion criteria; 
3. Variable: PFS (time from randomization to the earlier of disease progression or death) 
4. Population level summary: hazard ratio  
Intercurrent events under consideration: 1)NALT, 2) treatment discontinuation 
NALT and treatment discontinuation will all be ignored (treatment policy strategy). 
The main analysis will be based on investigators’ assessed PFS. Stratified Cox regression model 
with stratification factors chemotherapy and FLIPI1 will be used and treatment is included as the 
only independent variable in the regression model. The model assumption is proportional hazard 
ratio with each stratum, but the baseline risk may be different for different stratum. Patients will 
be censored at the last disease assessment if no PFS event is observed during the study 
(administrative censoring). 
 
X. Sensitivity analysis for the primary endpoint 
There are two planned sensitivity analyses that both target the primary estimand. The first will be 
to relax the assumption that chemotherapy and FLIPI1 are confounding factors, so the analysis 
will be repeated but unstratified, which implies the baseline risk is the same across strata The 
other sensitivity analysis is based on IRC assessed PFS and the same analysis as the main 
analysis will be performed.  This is to address the data limitation related to the assessment of the 
primary endpoint. 
X. Supplementary analysis for the primary endpoint 
There are three planned supplementary analyses. These are considered supplementary analyses 
as they inherently change the estimand. Per the ICH E9 addendum recommendations, only one 
thing per analysis is changed at a time 
The first supplementary analysis changes which strategy is employed for the intercurrent event 
of subjects who withdrawal. Withdrawal of obinutuzumab will be considered part of PFS 
definition and will be considered an event (composite strategy) and withdrawal of rituximab will 
be censored (hypothetical strategy) 
 The second supplementary analysis changes which strategy is employed for the intercurrent 
event of NALT. If a subject took a NALT they were censored (hypothetical strategy). 
The third supplementary analysis changes which strategy is employed for the intercurrent event 
of discontinuation of study treatment. If a subject discontinues study treatment prior to PD or 
clinical cutoff, it is considered an event as part of PFS (composite strategy). 
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